Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Child leukaemia survival boosted by mitoxantrone

  • Comment

The survival rates of child leukaemia patients whose cancer has returned can be significantly improved with the chemotherapy drug mitoxantrone, a study has shown.

The Cancer Research UK analysis found that giving mitoxantrone to children whose acute lymphoblastic leukaemia had returned increased survival rates after three years to 69%, compared with the 45% survival rate for standard treatment.

Following the study’s success, all children with the condition are now prescribed mitoxantrone. It was also found the drug has fewer side effects than the regular chemotherapy treatment idarubicin.

About 380 children are diagnosed with acute lymphoblastic leukaemia in the UK each year.

Professor Vaskar Saha, a child cancer specialist at the Paterson Institute in Manchester, who worked on the study, told The Lancet: “These striking results show just what a powerful drug mitoxantrone is in treating children whose leukaemia has returned, offering hope to many families across the country.”

Professor Martin Schrappe, of the University Medical Centre Schleswig-Holstein, said the 20% difference seen between the two groups was “one of the largest improvements ever achieved by a single modification of treatment”.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.